Addex Therapeutics Ltd (ADXN)

NASDAQ
Currency in USD
7.7400
0.0000(0.00%)
Closed
Pre Market
7.3600-0.3800(-4.91%)
ADXN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
7.49007.8600
52 wk Range
6.814227.9000
Key Statistics
Edit
Prev. Close
7.74
Open
7.755
Day's Range
7.49-7.86
52 wk Range
6.8142-27.9
Volume
4.05K
Average Vol. (3m)
37.99K
1-Year Change
-24.12%
Book Value / Share
0.13
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ADXN Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
30.0000
Upside
+287.60%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Addex Therapeutics Ltd Company Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The Charcot–Marie–Tooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Compare ADXN to Peers and Sector

Metrics to compare
ADXN
Peers
Sector
Relationship
P/E Ratio
−0.5x−1.2x−0.6x
PEG Ratio
0.000.000.00
Price / Book
0.6x1.2x2.6x
Price / LTM Sales
10.3x5.4x3.1x
Upside (Analyst Target)
287.6%146.4%48.2%
Fair Value Upside
Unlock12.1%8.0%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 30.0000
(+287.60% Upside)

Earnings

Latest Release
Apr 30, 2024
EPS / Forecast
-- / -0.0309
Revenue / Forecast
-- / 309.41K
EPS Revisions
Last 90 days

FAQ

What Is the Addex Therapeutics (ADXN) Stock Price Today?

The Addex Therapeutics stock price today is 7.74

What Stock Exchange Does Addex Therapeutics Trade On?

Addex Therapeutics is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Addex Therapeutics?

The stock symbol for Addex Therapeutics is "ADXN."

What Is the Addex Therapeutics Market Cap?

As of today, Addex Therapeutics market cap is 6.64M.

What is Addex Therapeutics Earnings Per Share?

The Addex Therapeutics EPS is 0.057.

From a Technical Analysis Perspective, Is ADXN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.